Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors

The field of genomics in myeloid malignancies and related implications in acute myeloid leukemia (AML) are evolving rapidly, and induction treatment strategies are now often guided by biological disease factors and fitness for intensive induction therapy. European LeukemiaNet (ELN) recommendations for the diagnosis and management of AML were updated in 2022 to reflect increasing knowledge on biological disease factors and prognosis and the impact of targeted therapeutic agents such as FLT3 and IDH inhibitors. Familiarity with up-to-date risk stratification and targeted therapies is essential when formulating induction treatment strategies for newly diagnosed AML. 

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Optimize treatment selection for patients with acute myeloid leukemia based on biological disease factors.
  • Describe unique toxicities of targeted therapies such as gemtuzumab ozogamicin, FLT3 inhibitors, and IDH inhibitors.
Additional information
Supporters: 

This activity is supported through educational grants from AstraZeneca; Bristol Myers Squibb; Genentech, a member of the Roche Group; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Novartis; Sanofi; Seagen; Servier Pharmaceuticals LLC; and Taiho Oncology, Inc. This educational activity is supported by a medical education grant from Karyopharm Therapeutics. This educational activity is supported by independent educational grants from AbbVie; Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an unrestricted educational grant provided by Prothena Biosciences Ltd, Dublin, Ireland, a member of the Prothena Corporation plc group. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.50 Participation
Course opens: 
12/01/2023
Course expires: 
12/01/2024
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2023 Annual Congress: Hematologic Malignancies™

Rebecca Olin, MD, MSCE
UCSF Helen Diller Family Comprehensive Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Rebecca Olin, MD, MSCE
Actinium Pharmaceuticals, Inc.: Consulting Fee 
Cellectis: Grant/Research Support
Rigel Therapeutics, Inc.: Consulting Fee 
Servier Laboratories: Consulting Fee

Congress Planning Committee Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
PharmaEssentia Corporation: Consulting Fee
Pharmaxis Ltd.: Consulting Fee
Protagonist Therapeutics Inc.: Consulting Fee
Pfizer Inc.: Consulting Fee

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

Bernard L. Marini, PharmD, BCOP
Servier Laboratories: Consulting Fee

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Honoraria

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics SA: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.50 contact hour, 0.50 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.050 CEUs) of continuing education credit. UAN: JA4008196-0000-23-114-H01-P 

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until December 1, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing